An article just published on line in Clinical Cancer Research supposedly reports the discovery of a single nucleotide polymorphism or SNP that may be useful in predicting which patients with Gleason 7 disease are most likely to have a more aggressive form of cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: aggressiveness, biomarker, Gleason, grade, KLK3, nucleotide, polymorphism, single, SNP | 1 Comment »
New data appear to suggest that you really don’t want to be diagnosed with high-risk prostate cancer if you are significantly over-weight or obese. … READ MORE …
Filed under: Uncategorized | Tagged: BMI, body mass, Gleason, mortality | 1 Comment »
It has frequently been postulated that the recommendations of the International Society of Urological Pathology (ISUP) consensus meeting in 2005 would lead to a gradual “upgrading” of all pathologically evident prostate cancers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Gleason, pattern, score, upstaging | 2 Comments »
Another study, just published in the British Medical Journal, appears to further debunk the idea that use of 5α-reductase inhibitors (5-ARIs) is associated with a significant increase in risk for development of high-grade prostate cancer. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5ARI, dutasteride, finasteride, Gleason, Prevention, risk | 2 Comments »
A new study report in Cancer Research suggests that: (a) prostate cancer aggressiveness may be established when the initial tumor is formed and not alter over time; (b) active surveillance or similar monitoring strategies really are the most appropriate initial management option for men with low-grade, low-risk cancer (potentially regardless of their age at diagnosis). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, Gleason, grade, mortality, risk, score, surveillance | 14 Comments »
The expertise of the pathologist assessing your prostate biopsy cores may make a major difference to the way you and your doctors think you need to be treated. Indeed the following data would suggest that many prostate biopsy samples should be examined by genitourinary pathologists who really specialize in prostate pathology. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Gleason, pattern, under-diagnosis | 2 Comments »
“Manserin” is a novel peptide originally derived from a larger secretory protein called secretogranin II. A newly published paper suggests that expression of manserin in human prostate cancer tissues may correlate with risk for clinically significant and progressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: expression, Gleason, immunohistochemistry, manserin, progression, risk | Leave a comment »
In recommendations made in association with a newly published study of the pathologiocal implications of “cribriform” prostate cancer tumors, Dr. Scott Lucia and colleagues are suggesting that all such tumors should be classified as Gleason grade 4 by definition. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: cribriform, Gleason, pathology, pattern | 1 Comment »
We have known for a while that men with a tertiary Gleason grade of 4 or 5 (as discussed below) are at heightened risk for progressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: Gleason, grade, pattern, prognosis, risk, tertiary | 1 Comment »
It has long been understood that men with a Gleason score (GS) of 7 could be divided into two groups: those with Gleason 4 + 3 disease (in which Gleason pattern 4 was more common or “dominant”) and those with Gleason 3 + 4 disease (in which Gleason pattern 3 was dominant). … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: biochemical, Gleason, pattern, progression, risk, score | 5 Comments »
In today’s news reports we note new articles dealing with:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bisphosphonate, dasatinib, denosumab, focal therapy, Gleason, saracatinib, tertiary, zoledronate | 7 Comments »
A review by Epstein in an upcoming issue of the Journal of Urology gives a detailed perspective on the current use of the Gleason grading system, with specific emphasis on the “removal” of Gleason patterns 1 and 2 in evaluating overall Gleason scores of biopsy samples and the value of “tertiary” Gleason pattern data. … READ MORE …
Filed under: Diagnosis, Management, Uncategorized | Tagged: Gleason, grade, modified, pattern, score, system | 8 Comments »
Jonathon Epstein, MD, at Johns Hopkins is widely considered to be one of the pre-eminent prostate cancer pathologists in the world today, so it is worth listening when he says that the Gleason grading system needs revision. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: Gleason, grade, outcome, revised, score | 4 Comments »
Burdick et al. have carried out a retrospective analysis of data from 705 patients with a pre-treatment biopsy Gleason score of 7 treated at the Cleveland Clinic between 1996 and 2005 to see if there was any difference in the outcomes of patients with a primary Gleason pattern of 3 (i.e., a Gleason score of 3 + 4 = 7) and those with a primary Gleason pattern of 4 (i.e., a Gleason grade of 4 + 3 = 7). Their data included men treated surgically and with different types of radiotherapy. … READ MORE …
Filed under: Management | Tagged: 3 + 4, 4 + 3, Gleason, grade, outcome, pattern | Leave a comment »
Today’s news items are focused on issues affecting risk for prostate cancer and risk for progression after treatment, and the ways these risks can be affected by available data:
Filed under: Diagnosis, Management, Prevention, Treatment | Tagged: downgrading, Gleason, NSAID, pathological, risk, score, upgrading | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 